One Drop announced today that new peer-reviewed research demonstrates sustained blood glucose reductions with its diabetes platform.
New York-based One Drop presented the clinical health outcomes associated with the long-term use of its digital diabetes offering at the Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Barcelona. The results demonstrated clinically sustained and statistically significant reductions in average blood glucose beyond six months and one year, reflecting meaningful reductions in estimated A1C.
According to a news release, members using One Drop for at least six months reduced their average blood glucose by 26.5 mg/dL, which translates to a 0.9% reduction in estimated A1C. Members who used One Drop for one year or more experienced a 35.2 mg/dL drop in average blood glucose, decreasing A1C by 1.2%.
The company estimates that its digital health platform improves health outcomes and offers estimated cost savings of $2,450 per person per year.
“Today’s healthcare model is untenable for people with chronic conditions and financially unsustainable for payers and health systems,” One Drop CEO and founder Jeff Dachis said in the release. “At One Drop, we look beyond the break-fix cycle of care and toward continuous, data-driven prevention by building connected medical devices and digital health solutions that proactively help individuals gain insights and inform decision-making in real time. Recent research affirms our precision health approach works.”
One Drop also noted that its future plans include a foray into the continuous health sensing market. The company currently has a proprietary sensor in development for giving members access to real-time health data. That sensor remains subject to regulatory approval.